According to the administration of the Buenos Aires province, a research done in Argentina found no significant adverse effects when the first component of the Russian coronavirus vaccine Sputnik V was combined with medicines from AstraZeneca and Sinopharm.
According to early findings from the current safety trial of mixing the Sputnik V vaccination with the medicines AstraZeneca and Sinopharm, no significant adverse effects have been found, according to the administration of the province of Buenos Aires, TASS reports.
The government has noted that following the second vaccine, 41.6 percent of study participants had not experienced any issues.
Per the Ministry of Health, at least 8.4 percent reported fever and back discomfort, with 50 percent reporting pain at the injection site.
The average age of participants in the research, which began on July 7, is 49 years old, the ministry underlined. Data on the effectiveness of the vaccination combination has yet to be acquired.
In Argentina, 24,919,053 people have gotten the first dose of the vaccine, and 6,865,086 people have been vaccinated with both doses. Sputnik V, along with vaccines from AstraZeneca and Sinopharm, is used to vaccinate the populace in Argentina.
